{
    "root": "303be450-cbff-7659-e063-6394a90a2052",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ZILBRYSQ",
    "value": "20250313",
    "ingredients": [
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
            "code": "593YOG76RN"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "22ADO53M6F"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "ZILUCOPLAN",
            "code": "YG391PK0CC"
        }
    ],
    "indications": "ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.",
    "contraindications": "Obtain baseline amylase and lipase. ( 2.2 ) For subcutaneous injection only. ( 2.3 ) Recommended dosage ( 2.3 ): Body Weight Once Daily Dosage Plunger Rod Color of Prefilled Syringe Less than 56 kg 16.6 mg RUBINE RED 56 kg to less than 77 kg 23 mg ORANGE 77 kg and above 32.4 mg DARK BLUE See Full Prescribing Information for instructions on dosage, preparation, and administration. ( 2.4 , 2.5 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "ZILBRYSQ is contraindicated for initiation in patients with unresolved serious\n \n   Neisseria meningitidisinfection\n \n   [see\n  \n    Warnings and Precautions (5.1)]\n \n   ."
}